Theralase Technologies Inc. (TLT) - Total Assets

Latest as of March 2026: CA$3.89 Million CAD ≈ $2.81 Million USD

Based on the latest financial reports, Theralase Technologies Inc. (TLT) holds total assets worth CA$3.89 Million CAD (≈ $2.81 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore TLT operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.

Theralase Technologies Inc. - Total Assets Trend (2001–2025)

This chart illustrates how Theralase Technologies Inc.'s total assets have evolved over time, based on quarterly financial data. See Theralase Technologies Inc. book value and equity for net asset value and shareholders' equity analysis.

Theralase Technologies Inc. - Asset Composition Analysis

Current Asset Composition (December 2025)

Theralase Technologies Inc.'s total assets of CA$3.89 Million consist of 58.0% current assets and 42.0% non-current assets.

Asset Category	Amount (CAD)	% of Total Assets
Cash & Equivalents	CA$0.00	5.2%
Accounts Receivable	CA$1.21K	0.0%
Inventory	CA$505.24K	14.5%
Property, Plant & Equipment	CA$0.00	0.0%
Intangible Assets	CA$0.00	0.0%
Goodwill	CA$0.00	0.0%

Asset Composition Trend (2001–2025)

This chart illustrates how Theralase Technologies Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Theralase Technologies Inc..

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Theralase Technologies Inc.'s current assets represent 58.0% of total assets in 2025, a decrease from 99.3% in 2001.
Cash Position: Cash and equivalents constituted 5.2% of total assets in 2025, down from 99.3% in 2001.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2001.
Asset Diversification: The largest asset category is inventory at 14.5% of total assets.

Theralase Technologies Inc. Competitors by Total Assets

Key competitors of Theralase Technologies Inc. based on total assets are shown below.

Company	Country	Total Assets
Shenzhen New Industries Biomedical SHE:300832	China	CN¥9.58 Billion
COCHLEAR LTD ADR 1/2/O.N. F:OC50	Germany	€2.83 Billion
GN Store Nord CO:GN	Denmark	Dkr29.23 Billion
4DMEDICAL Ltd AU:4DX	Australia	AU$139.55 Million
Getein Biotech Inc SHG:603387	China	CN¥3.70 Billion
Ningbo David Medical Device Co Ltd SHE:300314	China	CN¥1.45 Billion
Vieworks Co. Ltd KQ:100120	Korea	₩351.89 Billion
Somnomed Ltd AU:SOM	Australia	AU$79.90 Million

Theralase Technologies Inc. - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	1.37	0.82	8.37
Quick Ratio	1.11	0.52	7.64
Cash Ratio	0.00	0.00	0.00
Working Capital	CA$685.52K	CA$-299.94K	CA$6.31 Million

Theralase Technologies Inc. - Advanced Valuation Insights

This section examines the relationship between Theralase Technologies Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	36.39
Latest Market Cap to Assets Ratio	16.52
Asset Growth Rate (YoY)	7.6%
Total Assets	CA$3.49 Million
Market Capitalization	$57.75 Million USD

Valuation Analysis

Premium Asset Valuation: The market values Theralase Technologies Inc.'s assets at a significant premium (16.52x), suggesting investors see substantial growth potential or unique competitive advantages.

Positive Asset Growth: Theralase Technologies Inc.'s assets grew by 7.6% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Theralase Technologies Inc. (2001–2025)

The table below shows the annual total assets of Theralase Technologies Inc. from 2001 to 2025.

Year	Total Assets	Change
2025-12-31	CA$3.49 Million ≈ $2.53 Million	+7.63%
2024-12-31	CA$3.25 Million ≈ $2.35 Million	-0.91%
2023-12-31	CA$3.28 Million ≈ $2.37 Million	-21.25%
2022-12-31	CA$4.16 Million ≈ $3.01 Million	-30.01%
2021-12-31	CA$5.94 Million ≈ $4.30 Million	-40.67%
2020-12-31	CA$10.02 Million ≈ $7.25 Million	-35.22%
2019-12-31	CA$15.47 Million ≈ $11.19 Million	+334.01%
2018-12-31	CA$3.56 Million ≈ $2.58 Million	+7.27%
2017-12-31	CA$3.32 Million ≈ $2.40 Million	-46.76%
2016-12-31	CA$6.24 Million ≈ $4.51 Million	-12.13%
2015-12-31	CA$7.10 Million ≈ $5.14 Million	+86.06%
2014-12-31	CA$3.82 Million ≈ $2.76 Million	+42.17%
2013-12-31	CA$2.68 Million ≈ $1.94 Million	+137.04%
2012-12-31	CA$1.13 Million ≈ $819.34K	-19.72%
2011-12-31	CA$1.41 Million ≈ $1.02 Million	-56.41%
2010-12-31	CA$3.24 Million ≈ $2.34 Million	-22.77%
2009-12-31	CA$4.19 Million ≈ $3.03 Million	+31.72%
2008-12-31	CA$3.18 Million ≈ $2.30 Million	-14.18%
2007-12-31	CA$3.71 Million ≈ $2.68 Million	+0.61%
2006-12-31	CA$3.68 Million ≈ $2.67 Million	+3.81%
2005-12-31	CA$3.55 Million ≈ $2.57 Million	+192.12%
2004-12-31	CA$1.22 Million ≈ $878.97K	+97.59%
2003-12-31	CA$614.96K ≈ $444.85K	+527.06%
2002-12-31	CA$98.07K ≈ $70.94K	-33.10%
2001-12-31	CA$146.59K ≈ $106.04K	--

About Theralase Technologies Inc.

V:TLT Canada Medical Devices

Market Cap

$57.75 Million

CA$79.83 Million CAD

Market Cap Rank

#21334 Global

#742 in Canada

Share Price

CA$0.27

Change (1 day)

-5.26%

52-Week Range

CA$0.15 - CA$0.39

All Time High

CA$0.58